Jade Biosciences reports $336M cash; JADE101 Phase 1 data expected Q2 2026

Jade Biosciences, Inc.

Cash, equivalents, and investments of $336.2M as of Dec 31, 2025; runway into first half 2028.
Q4 2025 net loss $31.9M vs $30.1M Q4 2024; full year net loss $127.4M.
JADE101 Phase 1 interim data expected Q2 2026; Phase 2 IgA nephropathy trial to start mid-2026.
JADE201 (anti-BAFF-R) Phase 1 in rheumatoid arthritis expected Q2 2026; interim data 2027.
Raised ~$180M in Q4 2025 private placements from new and existing investors.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jade Biosciences, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $31.9 million for the fourth quarter ended December 31, 2025, compared to a net loss of $30.1 million f.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss totaled $31.9 million for the fourth quarter ended December 31, 2025, compared to a net loss of $30.1 million f
Result: reported results

Exact text from the filing

On March 6, 2026, Jade Biosciences, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-094967

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.